Clinical Trial Update: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant cisplatin-based chemotherapy plus concurrent atezolizumab in resected non-small cell lung cancer, with circulating tumor DNA a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Nasser Hanna | Conditions: Lung Cancer, NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING